Cleary, James M.;
Wolpin, Brian M.;
Dougan, Stephanie K.;
Raghavan, Srivatsan;
Singh, Harshabad;
Huffman, Brandon;
Sethi, Nilay S.;
Nowak, Jonathan A.;
Shapiro, Geoffrey I.;
Aguirre, Andrew J.;
D'Andrea, Alan D.
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
Beteiligte:
Cleary, James M.;
Wolpin, Brian M.;
Dougan, Stephanie K.;
Raghavan, Srivatsan;
Singh, Harshabad;
Huffman, Brandon;
Sethi, Nilay S.;
Nowak, Jonathan A.;
Shapiro, Geoffrey I.;
Aguirre, Andrew J.;
D'Andrea, Alan D.
Erschienen:
American Association for Cancer Research (AACR), 2021
Beschreibung:
<jats:title>Abstract</jats:title>
<jats:p>Pancreatic cancer is rapidly progressive and notoriously difficult to treat with cytotoxic chemotherapy and targeted agents. Recent demonstration of the efficacy of maintenance PARP inhibition in germline BRCA mutated pancreatic cancer has raised hopes that increased understanding of the DNA damage response pathway will lead to new therapies in both homologous recombination (HR) repair-deficient and proficient pancreatic cancer. Here, we review the potential mechanisms of exploiting HR deficiency, replicative stress, and DNA damage-mediated immune activation through targeted inhibition of DNA repair regulatory proteins.</jats:p>